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1. Introduction 
The study of the chemical nature of the ABH blood 
group antigens of the human erythrocyte membrane 
has been advanced in recent years by the isolation 
and characterization of several glycosphingolipids 
with blood group activity [l-3] . It has been reported 
that blood group ABH activity is present also in 
glycoproteins of the erythrocyte membrane [4-91. 
However, since these observations have been mainly 
based on serological inhibition tests, the presence of 
blood group-active glycolipids in the glycoprotein 
preparations cannot be excluded. Owing to the water 
solubility of the large-molecular size blood group- 
active glycosphingolipids (the poly(glycosyl)ceramides), 
it has been suggested that these glycosphingolipids 
may have been regarded in some studies as glyco- 
proteins [3]. The occurrence of protein-bound blood 
group ABH antigens in the erythrocyte membrane has 
therefore still been a matter of some controversy. In 
the present paper, we present direct chemical evidence 
for the occurrence of protein-bound blood group 
ABH antigens in the erythrocyte membrane. This 
was accomplished by the preparation of glycopeptides 
with pronase digestion from lipid-free membrane 
residues and the isolation of the blood group A- and 
B-active fractions using the a-galactosyl- and a-N- 
acetylgalactosaminyl-binding lectin [ 10,l l] of 
Bandeiraea simplicifolia (BS I lectin). The glyco- 
peptides are composed of about 50-60 sugar residues/ 
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molecule and contain an alkali-stable carbohydrate- 
peptide linkage. 
2. Methods 
Erythrocyte membranes were prepared from out- 
dated blood group A or B blood as in [ 121. The 
membranes were extracted with 83% ethanol and the 
dry residue was homogenized with 10 vol. 0.02 M 
phosphate buffer (pH 7.5) and 10 vol. butan-l-01 to 
solubilize the poly(glycosyl)ceramides [3]. The 
insoluble residue was further delipidated by homoge- 
nization in chloroform-methanol (2: 1 and 1:2, v/v). 
Glycopeptides were prepared from the dry lipid-free 
residue by extensive digestion with pronase [ 131, 
and purified by gel filtration after precipitation of 
polyanionic material with cetyl pyridinium chloride 
[141* 
The BS I lectin was isolated as in [lo] and coupled 
to (150 mg protein/l 5 ml gel) CNBr-activated 
Sepharose 4B (Pharmacia) at pH 8.3 as described by 
the manufacturer. The column was washed and equi- 
librated at 4°C with 10 mM Na-phosphate buffer 
(pH 7.0) containing 0.15 M NaCl and 0.1 mM CaCll 
(Pi/NaCl). The glycopeptides bound to the column 
were eluted with 5 mM galactose in PiNaCl. Frac- 
tionation of glycopeptides on concanavalin A- 
Sepharose was done as in [ 151. 
Monosaccharides were determined after methano- 
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lysis as their trimethylsilyl derivatives by gas-liquid 
chromatography [ 161. Long-chain (sphingosine) 
bases were determined by gas-liquid chromatography 
and mass spectrometry [ 171 and by mass fragmentog- 
raphy at m/e 174, which is a common fragment in 
the spectra of these substances. Amino acid analysis 
was performed by Dr Olli Simell, Children’s Hospital, 
University Central Hospital, Helsinki. 
The A and B blood group activities of glyco- 
peptides were determined in the standard hemag- 
glutination inhibition assay and the platelet ‘*‘I- 
labelled protein A test (PIPA) [ 181. In the latter 
assay the ability of glycopeptides to inhibit the 
binding of immune anti-A and anti-B antibodies on 
platelets of known AB groups was measured. Staphylo- 
coccal protein A labelled with “‘1 was used as a 
marker of platelet-bound IgG. Human immune anti-A 
and anti-B sera with titers of 3200 and 64 by Coombs 
agglutination test were used in dilutions 1:32 and 1:4, 
respectively. 
3. Results 
3.1. Isolation of ar-galactose-containing lycopeptides 
from blood group B active erythrocytes 
The yield of dry lipid-free membrane residue from 
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Fig.1. Fractionation of glycopeptides of blood group B-active 
erythrocytes on a column (1.4 X 10 cm) of BS I-Sepharose. 
TheW3 [Hlacetylatedglycopeptides were dissolved in Pi/NaCl 
and applied to the column equilibrated with the same buffer. 
Elution was carried out first with Pi/NaCl. At arrows, 5 mM 
and 500 mM @lactose were included in the buffer. Fractions 
of 6.0 ml were collected. 
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Fig.2. Gel filtration of glycopeptides bound to BS I lectin on 
a column (2 X 75 cm) of Sephadex G-50. The column was 
eluted with 0.1 M pyridine-acetic acid buffer (pH 5.0) and 
fractions of 4.6 ml were collected. For reference, the elution 
volumes (BD) Blue Dextran, (DE) Dextran T 10 (&fr 9400) 
(FE) fetuin glycopeptide (M, 3400), (TR) transferrin glyco- 
peptide (kfr 2400) and (ATR) asialotransferrin glycopeptide 
(kfr 1800) are shown. (----) Fraction B/BS+; (.-.-.) fraction 
A/ConA-A/B%; (-) fraction A/ConA-BIBS+. 
peptide fraction, which was prepared by pronase 
digestion of the lipid-free residue and purified by gel 
filtration, contained 17.7 pmol sugars/l00 mg lipid- 
free residue. Most of the glycopeptides (fraction 
B/BS-) passed through the BS I-Sepharose column 
(fig.1). The glycopeptides bound to the column 
(fraction B/BSt) were eluted with 5 mM galactose; 
no radioactivity was observed in fractions eluted with 
500 mM galactose. Fraction B/BS+ glycopeptides 
(1.48 ~01 sugar/100 mglipid-free membrane residue) 
was submitted to gel filtration on Sepharose G-50 
(fig.2). The glycopeptides were eluted slightly after 
the void volume. On the basis of the elution volume 
an app. mol. wt 10 200 was calculated for the glyco- 
peptides. The chemical composition of the glyco- 
peptides is given in table 1. The main sugar compo- 
nents were galactose and N-acetylglucosamine. No 
i\r-galactosamine was observed. 
Since the glycopeptides contained mannose, their 
possible binding to concanavalin A was tested by 
subjecting them to chromatography on a column of 
concanavalin A-Sepharose. Most of the glyco- 
peptides were not bound to the lectin. A small 
proportion of the material (5%) was obtained by 
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Table 1 
Chemical composition of the blood groupactive glycopeptides 
Constituent B/BS+ A/ConA-A/B% A/ConA-BIBS+ 
(moljmol glycopeptide) 
Fucose 1.0 5.5 4.6 
Mannose 2.0 2.4 2.1 
Galactose 24 20 18 
Glucose <0.2 <0.2 <0.2 
N-Acetylglucosamine 21 22 18 
N-Acetylgalactosamine <0.2 2.8 2.9 
Neuraminic acid 1.8 1.5 1.4 
Total sugars 56 54 48 
Aspartic acid 0.7 0.1 a 
Tbreonine 0.1 0.1 a 
Serine 0.2 0.1 a 
Glutamic acid 0.2 0.2 a 
Glycine 0.1 0.1 a 
Isoleucine 0.1 0.1 a 
Leucine 0.2 0.2 a 
Long chain bases <O.Ol <O.Ol <O.Ol 
a not determined 
In calculating the data, mol. wt 10 200, 10 000 and 8800 were used for fractions 
BIBS+, A/ConA-A/BS+ and A/ConA-BIBS+, respectively 
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elution of the column with 20 mM a-methyl-D- 
glucoside. Due to the scarcity of the material it was 
not subjected to further studies. 
3.2. Isolation of a-N-acetylgalactosamine-containing 
glycopeptides from blood group A-active 
cry throcy te 
The yield of dry lipid-free membrane residue from 
A erythrocyte was 98 mg/liter blood, and the puri- 
fiedglycopeptidescontained 16.1~01 sugars/l00 mg 
lipid-free residue. Fractionation of glycopeptides by 
affmity chromatography with the two lectins was 
performed in a reversed order as compared to that 
described for the blood group B glycopeptides. Thus, 
the glycopeptides were fust subjected to chromatog- 
raphy on concanavalin A-Sepharose. Three fractions 
were obtained: the glycopeptide fraction not bound 
to the lectin (fraction A/ConA-A) the fraction eluted 
with 20 mM ar-methyl-D-glucoside (fraction A/ConA-B) 
and the fraction eluted with 200 mM a-methyl-D- 
glucoside (fraction A/ConA-C) [ 151. Fractions 
A/ConA-A and A/ConA-B were subjected to chro- 
matography on BS I-Sepharose. The glycopeptides 
bound to the column (fractions A/ConA-A/BS+ and 
A/ConA-B/BSt) were eluted with 5 mM galactose. 
The yields of the bound glycopeptide fractions were 
1.41 and 0.28 ~01 sugar/100 mg lipid-free residue, 
respectively. 
The apparent molecular weights as determined by 
gel filtration (fig.2) were 10 000 and 8800 for the 
fraction A/ConA-A/BS+ and A/ConA-BIBS+ glyco- 
peptides, respectively. The chemical compositions 
are given in table 1. As a difference to the blood 
group B glycopeptides, the blood group A glycopep- 
tides contained N-acetylgalactosamine, and the 
proportion of galactose was lower. 
In order to study the possible alkali-lability of the 
glycopeptides, fraction A/ConA-A/BSt glycopeptides 
were treated with 0.05 M NaOH in 1 M NaBH4 for 
16 h at 45’C [ 191. The sugar composition and elution 
volume in gel filtration were unaffected by this 
treatment. Also, no N-acetylgalactosaminitol was 
detected. These data indicate that the N-acetyl- 
galactosamine residues were not involved in alkali- 
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labile 0-glycosidic bonds to the peptide, and that 
the carbohydrate-peptide linkage was stable to mild 
alkali treatment. 
3.3. Blood group activity of the glycopep tides 
The antigen activity of the glycopeptide fractions 
was determined by their ability to inhibit the agglutina- 
tion or red blood cells by natural antisera, and by 
their ability to inhibit the binding of class IgG anti-A 
antibodies to thrombocytes (table 2). The latter 
method was used because of its higher sensitivity. The 
data indicate that most of the blood group A-active 
glycopeptides from fractions A/ConA-A and A/ConA-B 
were bound to the BS I lectin, which is in agreement 
with the known specificity [ lo,1 l] of this lectin. 
Fraction ConA-C, which contains neutral mannose- 
rich glycopeptides [20] , did not contain blood group 
activity. Respectively, glycopeptides isolated from 
blood group B erythrocytes exhibited blood group B 
activity. However, a proportion of the activity was 
not bound to the BS I lectin, possibly due to over- 
loading of the column. 
Table 2 
Blood group A activitya of various glycopeptide fractions 
obtained from delipidated A erythrocyte membranes 
Fraction Blood group A activity 
HI PIPA 
titer % inhibition 
Con A-A +4 76 
Con A-A/BS-b - 51 
Con A-A/BS+C +8 100 
Con A-B - 19 
Con A-BIBS- - 0 
Con A-BIBS+ +4 100 
Con AC _ 0 
a The glycopeptide fractions showed no inhibitory activity 
when tested with B- or Oerythrocytes 
b Diluted 1 : 4; no inhibition 
c Diluted 1 : 6; 64% inhibition 
The activities were determined by the ability of the glyco- 
peptides to inhibit the hemagglutination of blood group A 
erythrocytes (H I) and their ability to inhibit the binding of 
anti-A antibodies to blood group A thrombocytes (PIPA). 
The amount of glycopeptides used corresponded to 25 mg 
lipid-free membranes residue except in Con-A-B which was 
obtained from 10 mg residue 
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4. Discussion 
The results indicate that blood group A and B 
antigens of the erythrocyte membrane occur not only 
in the form of glycolipids but also in glycoproteins. 
This inference is supported by the following findings: 
1. The blood group substances could be isolated after 
exhaustive delipidation of the membranes. 
2. The blood group-active substances did not contain 
glucose or long-chain (sphingosine) bases, which 
are integral constituents of the glycosphingolipids. 
3. The compounds isolated contained mannose and a 
proportion of the substances were also bound to 
concanavalin A. 
4. The fractions isolated contained amino acids with 
aspartic acid as the main component. 
5. From the fractions isolated with the aid of the BS I 
lectin, those from A but not from B erythrocytes 
containedN-acetylgalactosamine, and in an amount 
that cannot be explained by contamination of the 
glycopeptide fractions with glycosphingolipids. 
The blood group-active glycopeptides were of 
significantly larger molecular size than several known 
glycopeptides (reviewed [21] ). The glycopeptides 
differed also from the blood group substances of the 
ovarian mucins [22] in that they were stable to mild 
alkali treatment. The observation of aspartic acid as 
the main amino acid component suggests that the 
carbohydrate-peptide linkage is of the N-glycosidic 
type. Although alkali-labile A- or B-active carbohydrate 
units were not detected in the present study, the 
occurrence of such molecules in the glycopeptide 
fractions not bound to the BS I lectin cannot be 
be excluded. At least, a proportion of the erythrocyte 
membrane H activity has been ascribed to such chains 
191. 
The yield of the blood group-active glycopeptides 
was about 1.6 pm01 or 0.3 mg/liter blood. Thus they 
are present in amounts comparable to those reported 
for poly(glycosyl)ceramides, which are major blood 
group active glycolipids of the human erythrocyte 
membrane (0.6 mg/liter blood) [3]. The sugar com- 
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position and molecular size of the glycopeptides were 
I also very similar to these glycolipids. Since the glyco- 
peptides contained a high proportion of galactose and 
N-acetylglucosamine it is possible that they contain 
a repeating unit composed of these two sugars. Studies 
of the chemical structure of these novel type of 
carbohydrate units of glycoproteins are in progress. 
Preliminary data indicate many structural similarities 
to the poly(glycosyl)-ceramides. On the basis of this 
similarity, we propose to designate these glycopeptides 
poly(glycosyl)peptides. 
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